Lupin Limited (LUPIN)

Name: Lupin Limited (LUPIN) — histórico de demonstrações financeiras
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

Healthcare · Wall Street (EUA) · Última atualização: 2026-09-20

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies.

Números-chave

Capitalização de mercado: ₹952 billion
Receita (exercício encerrado em 2026-03-31): ₹274.9B
Lucro líquido: ₹53.3B
Margem bruta: 70.5%
Margem líquida: 19.4%

Ver gráficos interativos e demonstrações completas →

Demonstração de resultados anual

Demonstração de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Receita total	₹274.9B	₹221.9B	₹196.6B	₹162.7B
Lucro bruto	₹193.8B	₹147.4B	₹125.1B	₹90.1B
Resultado Operacional (EBIT)	₹68.2B	₹43.5B	₹28.0B	₹8.9B
Resultado líquido	₹53.3B	₹32.8B	₹19.1B	₹4.3B

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de LUPIN. /companies/us/LUPIN

Empresas semelhantes

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.